China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. has released its interim results, showcasing an increase in revenue to RMB 128.6 billion for the first half of 2024, up from RMB 122.8 billion in the previous year. Gross profits also rose to RMB 20.9 billion, though earnings per share saw a slight decrease from RMB 0.43 to RMB 0.41. The report indicates overall growth and stability in the company’s financial performance.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
